Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitors
Immune-checkpoint inhibitors (ICIs) exposed the oncology community to novel immune-related adverse events (irAEs). Here, we report on a retrospective analysis of patients with melanoma who developed an ICI-related, unilateral, acute and peripheral facial nerve paralysis (Bell’s palsy).We retrospectively reviewed all the cases of ICI-related Bell’s palsy in patients with melanoma treated at our institution from January 2015 to January 2020. A total of five cases of ICI-related Bell’s palsy were identified. Median age was 63 years. Median time-to-onset of Bell’s palsy from ICIs initiation was 15 weeks. Four patie...
Source: Melanoma Research - March 11, 2021 Category: Cancer & Oncology Tags: Short Communications: Clinical Research Source Type: research
Immunohistochemistry analysis reveals lysyl oxidase-like 3 as a novel prognostic marker for primary melanoma
Lysyl oxidase-like 3 (LOXL3) is an extracellular enzyme involved in the synthesis of collagen and elastin, and it has been reported to promote melanoma cell proliferation and invasion in vitro. However, the expression level of LOXL3 at different stages of melanocytic lesions and the role of LOXL3 in melanoma pathogenesis remain unknown. Immunohistochemical staining of LOXL3 in a tissue microarray of 373 biopsies at different melanocytic stages was conducted. The correlation between LOXL3 expression and patient survival was examined using Kaplan–Meier survival analysis. Univariate and multivariate Cox regression analyses ...
Source: Melanoma Research - March 11, 2021 Category: Cancer & Oncology Tags: Short Communications: Basic Science Source Type: research
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)
Conclusion
Ibrutinib did not induce any meaningful clinical benefit. ITK expression may not be clinically relevant. Treatment-refractory metastatic melanomas have other fundamental defects (i.e. absent PTEN and p16 expression, absent TILs) that may contribute to an adverse prognosis. (Source: Melanoma Research)
Source: Melanoma Research - March 11, 2021 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
Diagnostic and prognostic value of heat shock protein 90α in malignant melanoma
This study aims to evaluate diagnostic, therapeutic efficacy and prognostic value of plasma HSP90α levels in malignant melanoma. In this study, higher plasma HSP90α levels and abnormal rates were found in malignant melanoma patients than in healthy controls (92.63 vs. 51.84 ng/mL; P (Source: Melanoma Research)
Source: Melanoma Research - March 11, 2021 Category: Cancer & Oncology Tags: Original Articles: Translational Research Source Type: research
Metabolomic characterisation of progression and spontaneous regression of melanoma in the melanoma-bearing Libechov minipig model
Melanoma-bearing Libechov minipig (MeLiM) represents a large animal model for melanoma research. This model shows a high incidence of complete spontaneous regression of melanoma – a phenomenon uncommon in humans. Here, we present the first metabolomic characterisation of the MeLiM model comparing animals with progressing and spontaneously regressing melanomas. Plasma samples of 19 minipigs with progression and 27 minipigs with evidence of regression were analysed by a targeted metabolomic assay based on mass spectrometry detection. Differences in plasma metabolomics patterns were investigated by univariate and multivaria...
Source: Melanoma Research - March 11, 2021 Category: Cancer & Oncology Tags: Original Articles: Basic Science Source Type: research
Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10/STAT3 axis in melanoma tumor microenvironment
Myeloid-derived suppressor cells (MDSCs) suppress antitumor immune functions. We have observed that an immunomodulator, neem leaf glycoprotein (NLGP), inhibits tumor-resident MDSCs and enhances antitumor CD8+ T cell immunity. NLGP inhibits the number as well as functions of tumor-resident MDSCs (Gr1±CD11b±) and enhances antitumor CD8± T cell immunity by downregulating arginase 1 and inducible nitric oxide synthase production in MDSCs. Accordingly, decreased T cell anergy and helper to regulatory T cell conversion have been observed in the presence of NLGP, which ultimately augments T cell functions. Mechanistically, NLG...
Source: Melanoma Research - March 11, 2021 Category: Cancer & Oncology Tags: Original Articles: Basic Science Source Type: research
BAP1 deletion abrogates growth and metastasis of murine cutaneous melanoma
Although germline mutations in BRCA-associated protein-1 (BAP1) predispose to cutaneous melanoma (CM), BAP1 is rarely mutated in primary CM outside the familial context. The role of BAP1 in the pathogenesis of CM remains obscure. Here, we discovered an unexpected role of BAP1 in suppressing CM growth and metastasis. BAP1 deletion by CRISPR-Cas9 system severely compromises colony-forming capability of murine CM cell line B16-F10 and human CM cell lines, SK-MEL-28 and A375. Furthermore, BAP1 loss abrogates tumor growth and lung metastasis in murine syngeneic tumor models. Deletion of BAP1 in B16-F10 cells leads to preferenti...
Source: Melanoma Research - March 11, 2021 Category: Cancer & Oncology Tags: Original Articles: Basic Science Source Type: research
Mapping sentinel lymph nodes in cutaneous melanoma: a vast array of perioperative imaging modalities
Sentinel lymph node biopsy (SLNB) is a decisive step in the staging process of melanoma, critically impacting patients’ oncological outcome and driving the decision-making process. SLNB limits the extent of the dissection in cases where no metastases are found. Conversely, when metastases are detected, SLNB has the potential to improve regional control of the disease when complete lymphadenectomy or early administration of adjuvant treatment are indicated. Thus, accurately identifying sentinel lymph nodes represents an important prognostic factor. Several strategies have been studied, including novel procedures that are ...
Source: Melanoma Research - March 11, 2021 Category: Cancer & Oncology Tags: Review Article Source Type: research
Thirty years of therapeutic innovation in melanoma research
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - March 11, 2021 Category: Cancer & Oncology Tags: Editorial Source Type: research
KIT mutational status does not constitute an independent prognostic marker in cutaneous melanoma. A study on 688 Spanish patients
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - January 2, 2021 Category: Cancer & Oncology Tags: Letter to the Editor Source Type: research
Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature
Pembrolizumab is a humanized IgG4 isotype mAb that the targets and blocks the programmed cell death protein 1 receptor on lymphocytes. Its use in treating metastatic melanoma is associated with increased overall survival compared to other older immunotherapies. Several adverse effects have been noted including both systemic and cutaneous manifestations. As a relatively novel treatment option, many new cutaneous manifestations are still being observed, occurring at various times after initiation of therapy. Previously noted cutaneous adverse effects include sarcoid-like reactions, rash, and changes in preexisting lesions or...
Source: Melanoma Research - January 2, 2021 Category: Cancer & Oncology Tags: Short Communications Source Type: research
Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma
This report demonstrates a significant improvement in symptomatology and tumor stability with neoadjuvant anti-PD1 therapy for a retrocaval melanotic schwannoma initially masquerading as malignant melanoma. This report demonstrates the potential benefit of a novel therapeutic option for patients with melanotic schwannoma. (Source: Melanoma Research)
Source: Melanoma Research - January 2, 2021 Category: Cancer & Oncology Tags: Short Communications Source Type: research
Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report
Nowadays, anti-programmed death-1 (PD-1) antibodies are the first-line treatment for metastatic malignant melanoma. An infusion reaction is an adverse event that could occur due to monoclonal antibodies administration and requires prompt diagnosis and treatment. In this article, we report on a case of stage IV malignant melanoma treated with nivolumab, in which a severe infusion reaction occurred, manifesting as flushing and hypotension followed by bronchospasm. The switch to pembrolizumab was both a well-tolerated and effective therapeutic alternative. (Source: Melanoma Research)
Source: Melanoma Research - January 2, 2021 Category: Cancer & Oncology Tags: Short Communications Source Type: research
Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma
We present here a case of life-threatening polymyositis with associated spontaneous muscular hematoma in a patient treated with single-agent nivolumab in the adjuvant setting. Spontaneous hematoma is an extremely rare complication with unclear etiology of idiopathic myositis. Very few cases have been reported in the literature and their outcome has been often fatal. To our knowledge, this is the first case of autoimmune myositis and spontaneous heamatoma associated with the administration of single-agent checkpoint blockade. Anti-PD1 antibodies have changed the treatment landscape for a number of cancer entities in the pas...
Source: Melanoma Research - January 2, 2021 Category: Cancer & Oncology Tags: Short Communications Source Type: research
Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature
We report on a 68-year-old patient with malignant melanoma with lymph node metastases. Due to the lymphogenic progression, treatment was switched from nivolumab to dabrafenib and trametinib. Twenty-one days after initiation of BRAF/MEK inhibitor therapy, the patient presented to our emergency department with clinical signs of infection such as fever and fatigue. Laboratory tests showed excessive inflammation levels without identifying an underlying pathogen. Two days later, the patient developed an increasing pancytopenia. After extending the diagnosis, we found very high ferritin levels, hypertriglyceridemia, hypofibrinog...
Source: Melanoma Research - January 2, 2021 Category: Cancer & Oncology Tags: Short Communications Source Type: research
